Indaptus Therapeutics is trading 5.6% up today at $2.64 amid speculative trading and market volatility, as no specific company catalysts or regulatory headlines were reported.
- The gain follows a period of high volatility for the stock in early July, occurring while major market indices remain only slightly higher.
- Recent filings include a June 22 proxy statement and Q1 results, but there are no fresh updates regarding earnings, clinical trials, or financing.